Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1805sxm

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 3	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS 4	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 5	MAR 31	LPCI now available as a replacement to LDPCI
NEWS 6	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 7	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 8	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 9	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 10	APR 28	IMSRESEARCH reloaded with enhancements
NEWS 11	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS 12	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 13	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 14	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 15	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 16	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 17	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 18	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 19	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 20	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 21	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS 22	JUL 28	CA/CAplus patent coverage enhanced
NEWS 23	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 24	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 25	JUL 28	STN Viewer performance improved
NEWS 26	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS 27	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 28	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS 29	AUG 15	CAplus currency for Korean patents enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,

```
                AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:40:41 ON 20 AUG 2008

=> file medline caplus embase biotechno scisearch biosis
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.63       0.63

FILE 'MEDLINE' ENTERED AT 09:42:26 ON 20 AUG 2008

FILE 'CAPLUS' ENTERED AT 09:42:26 ON 20 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 09:42:26 ON 20 AUG 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'BIOTECHNO' ENTERED AT 09:42:26 ON 20 AUG 2008
COPYRIGHT (C) 2008 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 09:42:26 ON 20 AUG 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'BIOSIS' ENTERED AT 09:42:26 ON 20 AUG 2008
Copyright (c) 2008 The Thomson Corporation

=> s p2x2
L1          2066 P2X2

=> s l1 and antisense
L2            35 L1 AND ANTISENSE

=> dup rem l2
PROCESSING COMPLETED FOR L2
L3            23 DUP REM L2 (12 DUPLICATES REMOVED)

=> d ti 1-23

L3   ANSWER 1 OF 23  BIOSIS  COPYRIGHT (c) 2008 The Thomson Corporation  on STN
TI   P2X(3) receptors and sensory transduction.

L3   ANSWER 2 OF 23  CAPLUS  COPYRIGHT 2008 ACS on STN DUPLICATE 1
TI   Painful purinergic receptors

L3   ANSWER 3 OF 23  CAPLUS  COPYRIGHT 2008 ACS on STN
```

TI P2X3 receptors and sensory transduction

L3 ANSWER 4 OF 23 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
TI Ion channels in pain transmission.

L3 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
TI The peripheral modulation of nociceptive or pain signals mediated by P2X receptors

L3 ANSWER 6 OF 23 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
TI Pharmacology of P2X channels.

L3 ANSWER 7 OF 23 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
TI Purinergic control of neuropathic pain.

L3 ANSWER 8 OF 23 MEDLINE on STN
TI Inhibitory role of supraspinal P2X3/P2X2/3 subtypes on nociception in rats.

L3 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 2
TI Inhibitory role of supraspinal P2X3/P2X2/3 subtypes on nociception in rats

L3 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
TI P2X receptors: targets for novel analgesics?

L3 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
TI Treatment of neurological disorders by double-stranded RNA (dsRNA) administration

L3 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 3
TI P2X3 receptors and peripheral pain mechanisms

L3 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
TI Experimental investigation of P2 receptors and pain

L3 ANSWER 14 OF 23 MEDLINE on STN DUPLICATE 4
TI Chronic pain and microglia: the role of ATP.

L3 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
TI Method for identifying compounds to treat urological disorders by measuring their effect on disease-related genes and proteins, and use of the identified compounds in treatment

L3 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
TI Antisense oligonucleotides regulating rat and human purinoreceptor P2X3 gene expression and their use in pain therapy

L3 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
TI Contributions of P2X3 homomeric and heteromeric channels to acute and chronic pain

L3 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 5
TI ATP induced three types of pain behaviors, including allodynia

L3 ANSWER 19 OF 23 MEDLINE on STN DUPLICATE 6
TI Downregulation of P2X3 receptor-dependent sensory functions in A/J inbred mouse strain.

L3 ANSWER 20 OF 23 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
TI ATP-induced three types of pain behaviors including allodynia.

L3 ANSWER 21 OF 23 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
TI Peripheral and spinal mechanisms of alpha,beta-methylene ATP-induced mechanical allodynia in rats.

L3 ANSWER 22 OF 23 MEDLINE on STN
TI P2 receptors in the thymus: expression of P2X and P2Y receptors in adult rats, an immunohistochemical and in situ hybridisation study.

L3 ANSWER 23 OF 23 MEDLINE on STN DUPLICATE 7
TI Phosphorothioate oligodeoxynucleotides can selectively alter neuronal activity in the cochlea.

=> d ab 16 22 23

L3 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
AB The invention relates to antisense oligonucleotides, compns. and methods useful for modulating the expression of P2X2. The compns. comprise antisense oligonucleotides targeted to nucleic acids encoding P2X2.

L3 ANSWER 22 OF 23 MEDLINE on STN
AB The expression of the seven P2X receptor subtypes and of two P2Y receptors was examined immunohistochemically and by in situ hybridisation in thymi of adult male rats. P2X4, P2Y2 and 4 receptor mRNA colocalisation studies combining in situ hybridisation and immunohistochemistry were also carried out. P2X and P2Y receptors were found on thymocytes. P2X receptors were also abundant in cells of the thymic microenvironment, involved in control of T-cell maturation in vivo. We are the first to describe the expression of P2X4 receptors on thymocytes and confirm the finding of P2X1 and P2Y2 receptors on subpopulations of lymphocytes. P2X1,2,3,4 and 5 receptors were present in blood vessels of the thymus. P2X1,2 and 4 receptors were detected in vascular smooth muscle, while P2X3 receptors appeared to be associated with endothelial cells; some small arteries were positive for P2X5, possibly labelling vascular smooth muscle or fibroblasts in the adventitia. P2X2,3,6 and 7 receptors were found on thymic epithelial cells. P2X2 and 3 receptors were abundant on medullary epithelial cells, whilst P2X6 receptors were prominent in Hassall's corpuscles. P2X2 receptors were found on subcapsular and perivascular epithelial cells. P2X2,6 and 7 receptors were detected in epithelial cells along the thymic septa. Expression of P2X receptors was also investigated by Western blotting of crude thymic tissue extracts under reducing conditions. All seven P2X receptor subtypes were found to be dimers of approximately 70 kDa and 140 kDa molecular weight. ATP-mediated apoptosis and cell proliferation of thymocytes are discussed.

L3 ANSWER 23 OF 23 MEDLINE on STN DUPLICATE 7
AB A growing body of evidence indicates that extracellular adenosine triphosphate (ATP) may have a major role in cochlear function. Antagonists of ionotropic ATP receptors (P2X2) have significant effects on cochlear potentials and distortion product otoacoustic emissions (DPOAEs). We tested whether antisense oligodeoxynucleotides (ODNs) would mimic the functional deficiencies induced by the ATP antagonists through binding to P2X2 ATP receptor mRNA and thereby reduce the number of ATP receptors expressed in the membrane of the cells. Both a phosphorothioate ODN (S-ODN) antisense and a phosphodiester ODN (P-ODN) antisense to

the P2X2 sequence and random sense ODNs containing 21 nucleotides were administered chronically (7 days) to the guinea pig cochlea via the perilymph compartment. Sound evoked cochlear potentials (cochlear microphonic; summating potential; compound action potential of the auditory nerve, CAP; latency of the first negative peak in the CAP, N1 latency) and DPOAEs were monitored to assess the effects of the ODNs. Results indicate that the phosphorothioate derivatives of both the antisense and random sense ODNs suppressed the CAP and prolonged the N1 latency with no significant effect on the other parameters. The P-ODNs had no effect. Since both the antisense and random sense S-ODNs had the same effect, we conclude that the S-ODNs affected neuronal function in a manner that did not involve binding to the ATP receptor mRNA.

=> d 16 23

L3 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:551668 CAPLUS
DN 139:95485
TI Antisense oligonucleotides regulating rat and human purinoreceptor P2X3 gene expression and their use in pain therapy
IN Shuster, Samuel J.; Arvidsson, Ulf N. G.; Stone, Laura S.; Zhang, Hong-yan; Hart, Lucy Vulchanova
PA Algos Therapeutics, Inc., USA
SO PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003057898	A2	20030717	WO 2002-US41833	20021231
	WO 2003057898	A3	20031023		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002360847	A1	20030724	AU 2002-360847	20021231
	EP 1470145	A2	20041027	EP 2002-796136	20021231
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005514034	T	20050519	JP 2003-558191	20021231
	US 20080119423	A1	20080522	US 2004-500449	20041203
PRAI	US 2001-346155P	P	20011231		
	WO 2002-US41833	W	20021231		

L3 ANSWER 23 OF 23 MEDLINE on STN DUPLICATE 7
AN 1999419708 MEDLINE
DN PubMed ID: 10491959
TI Phosphorothioate oligodeoxynucleotides can selectively alter neuronal activity in the cochlea.
AU LeBlanc C S; Fallon M; Parker M S; Skellett R; Bobbin R P
CS Department of Otorhinolaryngology and Biocommunication, Louisiana State University Medical Center, New Orleans 70112-2234, USA.
NC T32-DC00007 (United States NIDCD)

SO Hearing research, (1999 Sep) Vol. 135, No. 1-2, pp. 105-12.
Journal code: 7900445. ISSN: 0378-5955.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
LA English
FS Priority Journals
EM 199911
ED Entered STN: 11 Jan 2000
Last Updated on STN: 11 Jan 2000
Entered Medline: 5 Nov 1999

=> d ab 15 19

L3 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
AB The present invention relates to methods for the diagnosis and treatment of a urol. disorder or urol. disorders. Specifically, the present invention identifies the differential expression of 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 and 6351 genes in tissues relating to urol. disorders, relative to their expression in normal, or non-urol. disorders, and/or in response to manipulations relevant to a urol. disorder. The present invention describes methods for the diagnostic evaluation and prognosis of various urol. disorders, and for the identification of subjects exhibiting a predisposition to such conditions. glucose. The invention also provides methods for identifying a compound capable of modulating a urol. disorder or urol. disorders. The present invention also provides methods for the identification and therapeutic use of compds. as treatments of urol. disorders.

L3 ANSWER 19 OF 23 MEDLINE on STN DUPLICATE 6
AB There is large variability in the various pain responses including those to tissue injury among inbred mouse strains. However, the determinant factors for the strain-specific differences remain unknown. The P2X3 sensory-specific ATP-gated channel has been implicated as a damage-sensing molecule that evokes a pain sensation by receiving endogenous ATP from injured tissue. In this study, to clarify the contribution of the sensory P2X3 signalling to strain-specific differences in tissue injury pain, we examined whether the P2X3-mediated in vivo and in vitro responses in dorsal root ganglion (DRG) neurons are changed in the A/J inbred mouse strain, which is known to be resistant to tissue injury pain caused by formalin. Here we found that A/J mice exhibited a low magnitude of nocifensive behaviour induced by the P2X agonist alpha,beta-methylene ATP (alpha beta meATP) into the hindpaw compared with C57BL/6 J mice. This behaviour was blocked by P2X3 antisense oligodeoxynucleotides. The low magnitude of the in vivo pain sensation could be observed similarly in the in vitro response; the increase in the intracellular Ca(2+) increase by alpha beta meATP in capsaicin-sensitive DRG neurons from A/J mice was significantly lower than that from C57BL/6 J mice. In A/J DRG neurons the P2X3 protein level was significantly lower compared with C57BL/6 J DRG neurons. The change in P2X3 protein was selective because P2X2 protein was expressed equally in both strains. The present study suggests that the downregulation of sensory P2X3 could be one of the molecular predispositions to low sensitivity to tissue injury pain in the A/J inbred mouse strain.

=> d 15 19

L3 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2003:590937 CAPLUS
DN 139:143886
TI Method for identifying compounds to treat urological disorders by measuring their effect on disease-related genes and proteins, and use of the identified compounds in treatment
IN Silos-Santiago, Inmaculada; Karicheti, Venkateswarlu
PA Millennium Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 242 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003061573	A2	20030731	WO 2003-US1450	20030116
	WO 2003061573	A3	20031231		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20030148394	A1	20030807	US 2003-345680	20030116
	EP 1472376	A2	20041103	EP 2003-731962	20030116
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005514940	T	20050526	JP 2003-561519	20030116
	US 20060088881	A1	20060427	US 2005-302678	20051214
PRAI	US 2002-349511P	P	20020118		
	US 2002-360500P	P	20020228		
	US 2002-365041P	P	20020315		
	US 2002-374063P	P	20020419		
	US 2002-403468P	P	20020814		
	US 2002-414262P	P	20020927		
	US 2002-419986P	P	20021021		
	US 2002-423809P	P	20021105		
	US 2002-429797P	P	20021126		
	US 2003-345680	B1	20030116		
	WO 2003-US1450	W	20030116		

L3 ANSWER 19 OF 23 MEDLINE on STN DUPLICATE 6
AN 2002323765 MEDLINE
DN PubMed ID: 12028354
TI Downregulation of P2X3 receptor-dependent sensory functions in A/J inbred mouse strain.
AU Tsuda Makoto; Shigemoto-Mogami Yukari; Ueno Shinya; Koizumi Schuichi; Ueda Hiroshi; Iwanaga Toshihiko; Inoue Kazuhide
CS Section of Neuropharmacology, Division of Pharmacology, National Institute of Health Sciences, Tokyo, Japan.
SO The European journal of neuroscience, (2002 May) Vol. 15, No. 9, pp. 1444-50.
Journal code: 8918110. ISSN: 0953-816X.
CY France
DT (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals

```
EM   200207
ED   Entered STN: 18 Jun 2002
     Last Updated on STN: 27 Jul 2002
     Entered Medline: 26 Jul 2002


=> s p2rx2
L4          25 P2RX2

=> s l4 and antisense
L5           0 L4 AND ANTISENSE

=> s purinergic receptor p2x
L6         148 PURINERGIC RECEPTOR P2X

=> s l6 and antisense
L7           3 L6 AND ANTISENSE

=> s l7 not l3
L8           3 L7 NOT L3

=> dup rem l8
PROCESSING COMPLETED FOR L8
L9             1 DUP REM L8 (2 DUPLICATES REMOVED)

=> d 1

L9   ANSWER 1 OF 1  EMBASE  COPYRIGHT (c) 2008 Elsevier B.V. All rights
     reserved on STN                                    DUPLICATE 1
AN   2005310641  EMBASE
TI   Mechanical strain opens connexin 43 hemichannels in osteocytes: A novel
     mechanism for the release of prostaglandin.
AU   Cherian, Priscilla P.; Siller-Jackson, Arlene J.; Gu, Sumin; Wang, Xin;
     Jiang, Jean X. (correspondence)
CS   Department of Biochemistry, University of Texas Health Science Center, San
     Antonio, TX 78229-3900, United States. jiangj@uthscsa.edu
AU   Sprague, Eugene
CS   Department of Radiology, University of Texas Health Science Center, San
     Antonio, TX 78229-3900, United States.
AU   Bonewald, Lynda F.
CS   Department of Oral Biology, School of Dentistry, University of Missouri,
     Kansas City, MO 64108, United States.
SO   Molecular Biology of the Cell, (Jul 2005) Vol. 16, No. 7, pp. 3100-3106.
     Refs: 39
     ISSN: 1059-1524  CODEN: MBCEEV
CY   United States
DT   Journal; Article
FS   029     Clinical and Experimental Biochemistry
LA   English
SL   English
ED   Entered STN: 5 Aug 2005
     Last Updated on STN: 5 Aug 2005


=> FIL STNGUIDE
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    60.68      61.31

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -1.60      -1.60
```

FILE 'STNGUIDE' ENTERED AT 09:55:36 ON 20 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Aug 8, 2008 (20080808/UP).

=>
=> logoff y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.10	63.41

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.60

STN INTERNATIONAL LOGOFF AT 10:16:36 ON 20 AUG 2008